Promethazine HCl Rectal Suppositories Rx
Generic Name and Formulations:
Promethazine HCl 12.5mg, 25mg, 50mg.
Various generic manufacturers
Indications for Promethazine HCl Rectal Suppositories:
Motion sickness. Perioperative nausea & vomiting.
Motion sickness: 25mg 30–60mins before travel; may repeat in 8–12hrs; maintenance 25mg twice daily. Perioperative nausea & vomiting: 25mg; may give additional doses of 12.5–25mg at 4–6hr intervals.
<2yrs: see Contraindications. Motion sickness: ≥2yrs: 12.5–25mg twice daily. Perioperative nausea & vomiting: 0.5mg/lb or 25mg; may give additional doses of 12.5–25mg or 0.5mg/lb at 4–6hr intervals.
Children <2yrs. Dehydrated or ill children (esp. Reye's syndrome). History of sleep apnea. Asthma and lower respiratory disorders. Uncomplicated nausea in children.
Glaucoma. GI or urinary obstruction. Cardiovascular or liver disease. Seizure disorders. Peptic ulcer. Bone marrow depression. Elderly. Children ≥2yrs. Pregnancy (Cat.C). Nursing mothers: not recommended.
Potentiates CNS depression with alcohol, other CNS depressants. Caution with MAOIs. May alter hCG pregnancy test results.
Drowsiness, lowered seizure threshold, cholestatic jaundice, anticholinergic and extrapyramidal effects, photosensitivity, hypo- or hypertension, rash, blood dyscrasias, nausea, neonatal platelet abnormalities; children: respiratory depression (may be fatal).
Formerly known under the brand names Phenergan (tabs, supps); Promethacon (supps).
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Outcomes in SCCHN Improved With Swap of Docetaxel for 5-FU in Palliative Regimen
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|